Juno Pharmaceuticals and Aspire Pharma are pleased to announce the acquisition of Specialty European Pharma (SEP), a pan-European specialty pharmaceutical and medical devices group. The acquisition came into effect June 22, 2016 and positions SEP to achieve long term growth through investment in their proprietary development portfolio, with short term goals including the launch of urethral bulking agent Bulkamid in the United States and EU approval of the synovial implant Athrosamid.
Ian Jacobson, Chief Executive Officer at Juno, said: “We are very excited about our acquisition of SEP and partnership with its management team. SEP’s niche product portfolio and strategic focus aligns perfectly with Juno’s corporate mission and we look forward to building on SEP’s impressive track record of growth. We view SEP as a company that has only begun to realize its considerable potential and we are confident that in partnership with its existing management team, we can build it into one of Europe’s leading pharmaceutical and medical device companies.”